Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
21.64
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Expert Ratings for Apellis Pharmaceuticals
↗
May 24, 2022
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
↗
May 24, 2022
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3%...
Via
Benzinga
Expert Ratings for Apellis Pharmaceuticals
↗
May 05, 2022
Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies
↗
March 16, 2022
Via
Benzinga
Earnings Scheduled For February 28, 2022
↗
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
↗
January 11, 2022
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
Apellis Pharmaceuticals's Earnings: A Preview
↗
May 03, 2022
Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Expert Ratings for Apellis Pharmaceuticals
↗
April 14, 2022
Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
↗
April 14, 2022
Upgrades
Via
Benzinga
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
↗
April 04, 2022
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.
Via
Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
↗
March 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
March 23, 2022
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the...
Via
Benzinga
Why Apellis Pharmaceuticals Stock Is Falling After Hours
↗
March 23, 2022
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million...
Via
Benzinga
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing
↗
March 16, 2022
If approved, this would be the company's second drug to hit the U.S. market.
Via
Investor's Business Daily
Here's Why Apellis Pharmaceuticals Shares Are Rising
↗
March 16, 2022
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
↗
March 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Expert Ratings For Apellis Pharmaceuticals
↗
March 07, 2022
Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks...
Via
Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
↗
March 07, 2022
Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Via
Benzinga
Apellis Pharmaceuticals: Q4 Earnings Insights
↗
February 28, 2022
Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Apellis Pharmaceuticals's Earnings Outlook
↗
February 25, 2022
Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement....
Via
Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
↗
December 15, 2021
The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan...
Via
Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
↗
December 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...
Via
Benzinga
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
↗
December 08, 2021
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
↗
December 08, 2021
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...
Via
Benzinga
Analyst Ratings For Apellis Pharmaceuticals
↗
November 29, 2021
Over the past 3 months, 8 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021
↗
November 29, 2021
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
↗
November 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 15, 2021
Gainers Kezar Life Sciences (NASDAQ:KZR) s...
Via
Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
↗
November 09, 2021
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
